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Broad coverage of the pathogen population is particularly important when designing CD8+
T-cell epitope vaccines against viral pathogens. Traditional approaches are based on com-
binations of highly conserved T-cell epitopes. Peptide block entropy analysis is a novel
approach for assembling sets of broadly covering antigens. SinceT-cell epitopes are recog-
nized as peptides rather than individual residues, this method is based on calculating the
information content of blocks of peptides from a multiple sequence alignment of homol-
ogous proteins rather than using the information content of individual residues. The block
entropy analysis provides broad coverage of variant antigens.We applied the block entropy
analysis method to the proteomes of the four serotypes of dengue virus (DENV) and found
1,551 blocks of 9-mer peptides, which cover 99% of available sequences with ﬁve or fewer
unique peptides. In contrast, the benchmark study by Khan et al. (2008) resulted in 165
conserved 9-mer peptides. Many of the conserved blocks are located consecutively in the
proteins. Connecting these blocks resulted in 78 conserved regions. Of the 1551 blocks of
9-mer peptides 110 comprised predicted HLA binder sets. In total, 457 subunit peptides
that encompass the diversity of all sequenced DENV strains of which 333 areT-cell epitope
candidates.
Keywords: antigenic diversity, epitope-based vaccines, immunoinformatics, polyvalent vaccines, reverse vaccinol-
ogy, vaccine informatics
INTRODUCTION
T-cell mediated immunity is a key factor in host responses against
human pathogens. It is important for clearance of infection and
for anticancer immunity. Peptide-based vaccines offer signiﬁcant
potential advantages in comparison to vaccines using whole pro-
teins or pathogens. These advantages include absence of infectious
agents, minimization of negative effects (such as oncogenicity
or allergenicity), minimal biological risk (such as reassortment,
recombination, or genome integration), ease of production and
quality control, and ﬂexibility in inclusion of peptides from mul-
tiple molecular targets and their variants (Purcell et al., 2007).
Peptides that are recognition targets of CTLs are proposed as
key components of the efforts to develop the next generation
of vaccines against various diseases including inﬂuenza (Brown
and Kelso, 2009), HIV (Barouch et al., 2010), and cancers (Pilla
et al., 2009). Despite signiﬁcant research effort, the develop-
ment of efﬁcient T-cell vaccines has proven difﬁcult (Appay,
2009). The obstacles related to antigenic targeting include diver-
sity of antigenic targets, human leukocyte antigen (HLA) diversity,
and availability of peptide targets, i.e., effectiveness of antigen
processing and presentation (Brusic and August, 2004; Riemer
et al., 2010). Conserved peptides have been studied as targets
for epitope-based vaccines in inﬂuenza (Tan et al., 2010), vari-
ola (Sette et al., 2009), hepatitis C (Yerly et al., 2008), and HIV
(Reche et al., 2006; Fischer et al., 2007; Nickle et al., 2007), among
others.
Reverse vaccinology (Rappuoli, 2000) provides a concep-
tual framework where vaccine targets are initially deﬁned from
pathogen proteomes using bioinformatics pre-screening, followed
by target selection and experimental validation (De Groot and
Rappuoli, 2004; Sette and Rappuoli, 2010). The scientiﬁc com-
munity has long been aware of the need for vaccine strategies
which address viral diversity (Hu et al., 1996). In highly variable
pathogens, such as HIV, inﬂuenza, or dengue, polyvalent vaccines
are considered as a solution to viral diversity (Fischer et al., 2007;
Morrison et al., 2010).
STRATEGIES FOR DEALING WITH HOST AND VIRAL DIVERSITY IN
VACCINE DESIGN
The design of broadly protective T-cell-based vaccines involves
identiﬁcation and selection of vaccine targets composed of
conserved antigens containing T-cell epitopes that are both pro-
tective and broadly cross-reactive to viral subtypes. The proposed
methods of consensus (CON; Gaschen et al., 2002; De Groot et al.,
2005), ancestor (ANC; Gao et al., 2005), and center of tree (COT;
Nickle et al., 2007) involve assembling individual amino acids into
“centralized” consensus sequences of viral proteins that compress
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antigenic diversity into a small set of artiﬁcial immunogens rep-
resentative of the virus population. Others, such as the mosaic
vaccine design (Fischer et al., 2007), cover viral diversity by assem-
bling naturally occurring peptides identiﬁed as T-cell epitopes
into artiﬁcial proteins, thereby collectively achieving polyvalent
coverage. Mosaic vaccines have been tested in preclinical trials
with rhesus monkeys showing that these immunogens can induce
responses against peptide targets (Barouch et al., 2010; Santra
et al., 2010). Common to these methods is a systematic inclu-
sion of highly conserved epitope candidates and exclusion of rare
peptides, despite the fact that it has recently been demonstrated
that MHC class I epitopes in the ﬂaviviruses have exceptionally
low targeting efﬁciency (i.e., low correlation between MHC bind-
ing afﬁnities and conservation of the targeted proteomic regions;
Hertz et al., 2011). Furthermore, some low frequency peptides have
been shown to be favorable T-cell epitopes in HIV (Rolland et al.,
2011). The exclusive focus on highly conserved epitope candi-
dates, for example those maintained in 90% or more of sequences,
presents a serious limitation in target selection in dengue virus
(DENV) and in other virus species that have multiple serotypes
or clades (such as HIV and inﬂuenza). In these viruses position
many peptides may be intra-clade conserved, but not inter-clade
conserved.
A large-scale systematic analysis of peptide conservation and
diversity using Shannon entropy calculation and prediction of
HLA speciﬁcity for conserved peptides in DENV proteins was pre-
viously performed for identiﬁcation of conserved T-cell epitope
candidates (Khan et al., 2008). The authors sought to ﬁnd pep-
tides of nine residues or longer in length, conserved in a minimum
of 80% of the 12,404 DENV protein sequences in their dataset.
They identiﬁed 44 such peptides, of which 34 were conserved
in more than 95% of their dataset. They furthermore showed
that a subset comprising 34 of the 44 sequences contained 9-
mer peptides which were computationally predicted to bind HLA
molecules thus representing candidate HLA super type-restricted
T-cell epitopes.
Our study extends the analysis of conservation and variabil-
ity of the DENV proteome. Its focus is the identiﬁcation of
pools of peptides that broadly cover both intra-serotype and
inter-serotype diversity. In DENV, the vast majority of experimen-
tally validated epitopes are not conserved across the proteome of
all four serotypes. Yet, an efﬁcient vaccine against DENV infec-
tion must be protective against all four serotypes. Therefore,
the optimal assembly of vaccine targets presents a combinator-
ial problem where conservation of antigens, diversity of possible
HLA interactions, and functional relevance of individual pep-
tides must be assessed. Furthermore, tetravalent formulations
(Guy et al., 2010; Murrell et al., 2011) represent main candi-
date dengue vaccines currently in development. Despite 60 years
of research, effective dengue vaccine is not yet available (Mur-
rell et al., 2011). We, therefore, developed and deployed a set
of analytical tools to identify, assess, and combine peptide pools
suitable for vaccine targeting. It is well-established that the com-
plications associated with secondary infection involve humoral
immunity (Halstead and O’rourke, 1977; Halstead et al., 1977),
and that immunity against DENV is primarily antibody medi-
ated. Recent research has shown that cellular immunity also
plays a role in these complications (Duangchinda et al., 2010),
and that cross-reactive DENV-speciﬁc T-cells may contribute
to the development of dengue hemorrhagic fever (DHF). In
this paper we focus on identifying T-cell epitopes, although the
block entropy method can be readily used for identiﬁcation of
both linear and discontinuous motifs such as functional B-cell
epitopes.
Human CD8+ T-cell epitopes and naturally processed HLA
ligands are, with only a few exceptions, 8–11 residues long (Ram-
mensee et al., 1999). CD4+ T-cell epitopes bind HLA molecules
mainly through the 9-mer binding core while ﬂanking residues
modulate binding (Brown et al., 1993). Therefore, the variabil-
ity and conservation of antigens should be examined for peptides
rather than for individual residues. Block entropy calculations –
i.e., calculating information content of a set of aligned sequences –
have previously been applied to the analysis of motifs in DNA
sequences (Lio et al., 1996). Also, the entropy of 9-mer peptides
can be derived from values of individual positions determined
using center of the 9-mer calculation (Khan et al., 2008). We
applied similar formula for entropy calculations for 8-, 9-, 10-,
and 11-mer peptides as blocks. The peptide block entropy method
is based on calculating the entropy of blocks of peptides and
frequency of individual peptides in a multiple sequence align-
ment (MSA) of homologous viral protein sequences. The block
entropy analysis becomes a useful tool when searching for con-
served peptides; for example, a given block may contain only
two unique peptides at 50% frequency each, but despite such a
modest variability these peptides will not be deemed conserved
using the approach that considers conservation of individual
amino acids, as used in previous efforts (Fischer et al., 2007;
Khan et al., 2008). Because peptide blocks are extracted from
a MSA of homologous protein sequences from DENV, a rel-
atively high level of homology of the peptides is expected to
be found within an average block. Blocks of homologous pep-
tides are more likely to display similar binding afﬁnity to the
HLA class I than randomly assembled sets of non-homologous
peptides. However, certain residue variation(s), such as T-cell
epitope anchor positions (Falk et al., 1991), can signiﬁcantly
change binding afﬁnity. Similarly, the regions surrounding the
block are likely to display inter-sequence homology, suggesting
blocks of peptides are more likely to have similar processing
characteristics, including proteasomal cleavage and TAP afﬁnity
(Martinez et al., 2009), than randomly assembled peptide pools. A
block consisting of several epitope candidates with the combined
capacity to cover the diversity of all known DENV strains could
therefore be a valuable target for prophylactic polyvalent vaccine
design.
MATERIALS AND METHODS
VARIABILITY AND CONSERVATION METRICS
The calculation of information content of residues in a MSA
of homologous protein sequences is based on the calculation of
Shannon entropy (Shannon, 1948):
H (x) = −
I∑
i=1
Pi(x) log2(Pi(x)) (1)
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where H is the entropy, x is the position in the MSA, i represents
a given individual amino acid at position x, I is the number of
different amino acids on position x, and Pi(x) is the frequency of
amino acid i at position x. The conservation of a given position
is deﬁned as the frequency of the consensus amino acid (most
frequent at a given position).
BLOCK ENTROPY AND CONSERVATION
Shannon entropy can be calculated for each peptide in a block.
Each block contains a total of W unique peptides of length l in a
dataset of N sequences of length L.We can thus extract L–l blocks,
B, of N or fewer unique peptides. The application in conservation
analysis is the identiﬁcation of peptides, which together as a sub-
set, Sw, of W represents a given fraction of W. The formula for
calculation of block entropy is:
H (Bx ) = −
W∑
w=1
Pw (x) log2(Pw (x)) (2)
Where H (Bx) is the total entropy of a block of peptides start-
ing at position x, w is a single unique peptide in the space of W
unique peptides in block Bx. Pw(x) is the frequency of peptide w
at position x.
Four variables are used to classify a block as conserved or not
conserved:
1. the minimum number of unique peptides, u, required to reach
a pre-deﬁned cumulative frequency in the block in which they
are found;
2. the minimum percentage, yx, of a block that must be cov-
ered by the subset of peptides, Su, for a block to be considered
conserved;
3. the maximum allowed fraction, gx, of peptides containing gaps
in the block;
4. the minimum percentage with which each serotype should be
covered individually, sx.
In this analysis we used u = 5, yx = 0.99, gx = 0.01, and
sx = 0.99. The peptides which are collectively only present in
1% of all sequences (1− yx) are unlikely to be stable peptides
and many may also be data noise originating from sequenc-
ing errors, database entry errors, etc. Assuming that the sub-
set of peptides which collectively occur in less than 1% of
known sequences represent variants of low ﬁtness, sequencing
errors, or rare variants, we consider that 99% coverage rep-
resents a practical threshold for complete conservation. The
identiﬁcation of conserved blocks is combined with the assess-
ment of HLA binding potential for each peptide in each block.
Blocks in which all peptides, u, in Su show similar binding
afﬁnity to the same HLA molecule, are classiﬁed as “immuno-
functionally conserved.” Blocks in which not all u in Su are
predicted as HLA binders with the same HLA restriction were
discarded.
PREDICTION OF PEPTIDE BINDING TO MHC CLASS I
Human leukocyte antigen binding afﬁnities of peptides in con-
served blocks were predicted using NetMHC 3.2 (Lundegaard
et al., 2008). Binding afﬁnity to HLA class I was predicted
for peptides of nine residues long for the following HLA alle-
les: HLA-A*0201, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02,
HLA-B*07:02, HLA-B*08:01, HLA-B*15:01. These HLA class I
alleles were selected for the analysis because NetMHC3.2 pre-
dictions of peptide binding to these variants were shown to
be highly accurate (Lin et al., 2008). The default thresholds
for binding level afﬁnity (IC50 < 500 nM for weak binders and
IC50 < 50 nM for strong binders) were used for binding clas-
siﬁcation in this study. Thus a minimum binding afﬁnity of
500 nM was required for a peptide to be considered a potential
binder.
DEALING WITH ALIGNMENT GAPS AND AMBIGUOUS CHARACTERS IN
THE MSA
Gap insertions in the alignment correspond to insertion or dele-
tion (indel) variation in one or more sequences in the dataset.
The DENV diversity is generally caused by substitution mutations
rather than indels, but some gaps were observed. Indels of residues
can lead to signiﬁcant change of binding potential or, if both vari-
ants are binders, completely different T-cell recognition (Riemer
et al., 2010). Therefore, in block entropy based conservation analy-
sis we consider blocks with gaps problematic. In most cases gaps
in the alignment were caused by a fraction of the sequences lower
than 1% (rare sequences) which were simply removed. If gaps
could not be eliminated in this way, the blocks in which more than
1% of the peptides contained gaps were considered too variable
and were classiﬁed as not conserved. Similarly, peptides contain-
ing ambiguous amino acid characters (such as “X”) were omitted
from the analysis.
SEQUENCE LOGOS
Weused sequence logos to visualize the information content (mea-
sured in bits) of each position within the blocks (Schneider and
Stephens, 1990). Sequence logos are visual representations of the
Shannon entropy of the positions within a given sequence. The
theoretical maximum entropy of a position in a protein sequence
is log220≈ 4.32 (corresponding to equal representation of all 20
amino acids), so each amino acid on a position can be repre-
sented by its fractional information content of the maximum.
To generate sequence logos we used WebLogo (Crooks et al.,
2004).
BLOCK LOGOS
We designed a logo for visualizing information content of blocks
bymodifying the sequence logo representation. Sequence logos are
very informative about the occurrence of residues on each posi-
tion, but do not carry valuable information about the frequencies
of peptides. Since the theoretical maximum entropy of a block of
unlimited size is log2209 ≈ 39 (corresponding to an equal repre-
sentation of all possible 9-mers),we use the total entropy,H (B), of
a block as themaximumbit on the y axis. The information content
of each unique peptide, w, in each block, Bx, can be calculated as
follows:
H (w) = Pw (x)H (Bx ) (3)
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where H (w) is the entropy of peptide w, Pw(x) is the frequency
of peptide w, and H (Bx) is the total entropy of the block,
B, starting at position, x, in the MSA. The peptides are dis-
played from most to least frequent starting from the base of the
x axis.
DENV SEQUENCES AND T-CELL EPITOPE DATA
The immune epitope database (IEDB;Vita et al., 2010)was queried
for known DENV MHC class I binders. For the block entropy
analysis we used only completeDENVprotein sequences extracted
from GenPept (Benson et al., 2010). These sequences were aligned
using MAFFT (Katoh and Toh, 2008). Individual protein prod-
ucts were annotated only in a small fraction (roughly 30%) of
the polyprotein sequences retrieved from NCBI. The remaining
proteomes were annotated using annotation from GenPept ref-
erence sequences within the MAFFT alignments. The sequences
were deposited in an in-house, publically available database for
easy access <cvc.dfci.harvard.edu/ﬂavi> (Olsen et al., 2011). The
numbers of sequences classiﬁed by protein and serotype are listed
in Table 1.
Due to samplingbias andnatural frequencydifferences between
the four serotypes of DENV, sequences for the serotypes were not
Table 1 | Sequence data used in this analysis.
Protein DENV serotype Total
1 2 3 4
anC 1235 872 739 189 3035
prM 1235 933 742 194 3104
E 1759 1487 1011 409 4666
NS1 1226 912 595 106 2839
NS2A 1241 839 565 105 2750
NS2B 1241 838 565 105 2749
NS3 1214 838 565 105 2722
NS4A 1214 837 566 105 2722
2K 1214 838 566 105 2723
NS4B 1213 838 566 105 2722
NS5 1209 835 566 105 2715
Total 14001 10067 7046 1633 32747
found in similar numbers. For example, relatively small number of
available DENV4 sequences meant that extra care was required to
ensure that DENV4 diversity was covered properly. We therefore
adjusted the size of the datasets of DENV2, DENV3, and DENV4
simply by multiplying the datasets of less frequent serotypes to
match themost frequent serotype,DENV1.Upon inspectionof the
adjusted dataset, we concluded that no further signiﬁcant strain
redundancy was present.
RESULTS AND DISCUSSION
CONSERVATION OF KNOWN T-CELL EPITOPES
Querying the IEDB database (Vita et al., 2010) for experimen-
tally determined DENV CD8+ T-cell epitopes yielded a list of
190 veriﬁed 9-mer T-cell epitopes. The average conservation of
known T-cell epitopes across the DENV1–4 proteins was 37.13%.
Only 18 (10%) of all known epitopes are found in >90% of
the DENV1–4 strains (Figure 1). Thus only 10% of the known
epitopes would be included as potential vaccine targets using a
residue-based deﬁnition of conservation.
SUMMARY OF CONSERVED PAN-DENV PEPTIDE BLOCKS
We analyzed all blocks of 8, 9, 10, and 11 residues long in the MSA
of DENV polyproteins. For each block we calculated the block
entropy, the minimum number of peptides needed to cover 99%
of a block, the coverage of each of the four DENV serotypes, and
also identiﬁed the total number of peptides in each block. The
conservation of 8-, 9-, 10-, and 11-mer blocks is summarized in
Table 2.
There are 1,732, 1,551, 1,394, and 1,245 conserved blocks of
8-, 9-, 10-, and 11-mer peptides respectively. Khan et al. (2008)
identiﬁed 206, 165, 118, and 88 conserved 8-, 9-, 10-, and 11-mer
peptides, respectively, by their criteria for conservation (individ-
ual peptides conserved in 80% or more sequences). Using peptide
block entropy approach to conservation analysis, we found an
approximately 10-fold larger conserved target space, which can
be examined for potential T-cell epitope candidates. We found
the conserved blocks in anC, prM, NS2A, NS2B, NS4A, and 2K
proteins, which have previously been considered as too variable
for mapping T-cell epitope candidates for cross-protective vaccine
constructs.
FIGURE 1 |The frequency of the 190 known epitopes sorted from most to least frequent.
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By using the conservation thresholds deﬁned in the Section
“Materials and Methods,” we examined each protein for
conservation of blocks. The number of peptides (9-mers) required
to cover 99% of the block for each position in the proteome is
shown in Figure 2. Peptide block conservation relative to protein
length was highest in the NS4B and lowest in NS2A proteins. In
NS4B, 166 blocks of 9-mers (69.1% of blocks within this pro-
tein) were conserved whereas NS2A showed only 8.83% block
conservation.
The average entropy for blocks of 9-mer peptides was
1.70± 0.71. This is almost double the entropy of individual
positions where values larger than 1 indicate highly vari-
able positions (Koo et al., 2009). The entropy of blocks,
with only a very few exceptions, where ﬁve or less pep-
tides are required to cover 99% of sequences within a block
is as high as 2.4 bits (Figure 3). This indicates that the
block entropy analysis is a robust method, making it suit-
able for identiﬁcation of conserved regions of antigenic pro-
teins, where antigenic diversity can be covered by a small
number of peptides. This result shows that block entropy
analysis is suitable for target selection in polyvalent vaccine
formulations.
Table 2 |The total number of blocks which covers 99% of the sequences with five peptides or less, as well as the relative distribution of
numbers of peptides in each block.
Peptide
length
Total number
of blocks
Blocks with 99% coverage
with ≤5 peptides
Distribution of number of peptides in blocks
1 peptide 2 peptides 3 peptides 4 peptides 5 peptides
8 3393 1732 199 355 388 460 330
9 3392 1551 142 319 341 435 314
10 3391 1394 102 278 295 418 301
11 3390 1245 75 228 266 386 290
This table is a summary of block of 8, 9, 10, and 11-mer peptides.
FIGURE 2 | (A)The number of 9-mer peptides required to cover 99% of a block, for each possible start position in the proteome. (B)The number of 9-mer
peptides required to cover 99% of a block, sorted in increasing order.
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BLOCK INFORMATION CONTENT
Weexamined the information content of individual blocks.Table 3
shows a representative 9-mer block (position 388 of the MSA of
NS3 proteins). We calculated the frequency and information con-
tent of each peptide in the block and assessed serotype distribution
of these peptides. Five peptides are needed to cover >99% of the
sequences within this block, covering approximately 65, 29, 4, 1,
and 0.3% of sequenced DENV strains respectively. None of these
peptides would have been included in a traditional conservation
analysis, in which 80–90% is a typical conservation threshold. This
analysis also brings an insight into the effects of threshold selec-
tion. If a loose block conservation threshold was used (90%), the
three least frequent peptides in the MSA would be excluded and
this would exclude DENV4 peptides from the target set. The 99%
threshold, on the other hand, would exclude only extremely rare
peptides across DENV1–3 serotypes. The peptide number 5 was
only found in ﬁve strains isolated in Senegal from the late 1960s
and three strains from Nigeria from late 1990s. Peptide 5 there-
fore appears to be a geographically and historically isolated low
ﬁtness variant. Peptides 3 and 4were,however, found in strains iso-
lated almost every year from 1944 to present, and 1983 to present,
respectively. Furthermore, peptides 3 and 4 were found distrib-
uted across Asia and Australasia and peptide 3 was also observed
in Latin America and parts of South America. It is therefore highly
likely that strains containing these particular peptides will resur-
face again given that geographic barriers to spread of DENV are
diminishing in the wake of climate changes and increased travel.
We, therefore, expect that these strains will continue to spread and
FIGURE 3 | X,Y scatter plot of the number of peptides required for 99%
coverage of a given block, against the entropy of each given block.The
black diamonds correspond to blocks in which no peptides are predicted to
bind to the HLA. The blue circles indicate that some, but not all, peptides
within that block are predicted to be epitopes.The red squares indicate that all
peptides within the block are predicted to bind the same HLA type.
Table 3 | Details of the peptides observed in block 388 of the NS3 protein.
# Peptide Frequency Acc. frequency Bits HLA binding (nM) Serotypes containing peptide (%)
1 KTFDTEYQK 65.03 65.03 0.84 A*03:01(59.69); A*11:01(5.41) DENV1(99.67) DENV3(99.32)
2 KTFDSEYVK 28.69 93.72 0.37 A*03:01(51.48); A*11:01(7.19) DENV1(0.08) DENV2(92.64)
3 KTFDTEYPK 3.82 97.54 0.05 A*03:01(26.17); A*11:01(3.35) DENV4(100)
4 KTFDSEYIK 1.18 98.71 0.02 A*03:01(71.55); A*11:01(8.59) DENV2(4.19)
5 KTFDTEYTK 0.29 99.01 0.00 A*03:01(37.45); A*11:01(4.65) DENV2(0.95)
6 KTFDSEYAK 0.29 99.30 0.00 Not predicted DENV2(0.95)
7 KTFDTEYIK 0.26 99.56 0.00 Not predicted DENV2(0.90)
8 RTFDTEYQK 0.11 99.67 0.00 Not predicted DENV1(0.25)
9 KTFETEYQK 0.11 99.78 0.00 Not predicted DENV3(0.17)
10 KTFDAEYVK 0.07 99.85 0.00 Not predicted DENV2(0.25)
11 KTFNTEYQK 0.07 99.93 0.00 Not predicted DENV3(0.34)
12 KTFDTEYQR 0.04 99.96 0.00 Not predicted DENV3(0.17)
13 KTFDFEYIK 0.04 100 0.00 Not predicted DENV2(0.12)
Peptide 1 (KTFDTEYQK) is a known ligand for HLA-03, -11, and -31. Furthermore, peptides 2–5 are predicted to have similar binding afﬁnity to peptide 1 for HLA-A3
supertype alleles using MULTIPRED2 (Zhang et al., 2011).
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proliferate across the world (Mackenzie et al., 2004; Franco et al.,
2010).Modern vaccine development clearly requires variant inclu-
sion beyond target selection resulting from a simple conservation
analysis. Block entropy analysis enables identiﬁcation and further
analysis of historical strains, while it is much more difﬁcult to
identify relevant low frequency peptides using individual position
analysis.
We compared conservation analysis using block entropy with
the analysis based on frequency of individual positions. This com-
parison can be supported by the visualization tools; the sequence
logo (Crooks et al., 2004) and our new tool, the Block Logo
(Figure 4). From the sequence logo one can picture a combinator-
ial space in which up to eight different peptides maybe present.
From the block logo we can see that only two peptides cover
94% while only four peptides within the block show any notable
presence.
PREDICTION OF HLA BINDING OF CONSERVED DENV PEPTIDE BLOCKS
Binding afﬁnities were predicted for each of the 5,113 peptides in
the 1,551 blocks of conserved 9-mer peptides. If all peptides in a
blockwere predicted to bind to the sameHLA type,we consider the
block“immuno-functionally conserved”(further deﬁned inMate-
rials and Methods). In total 110 blocks, comprising 333 peptides,
were predicted to be immuno-functionally conserved. The distri-
bution of immuno-functionally conserved peptides from different
proteins with the number of peptides in each block is shown in
Table 4.
The antigenic potential differs between individual proteins, as
shown by the number of predicted epitope blocks relative to the
size of the protein (Table 5). A protein that has a high conserva-
tion to size ratio is traditionally assumed to have high antigenic
potential for vaccine design. Proteins NS3, NS5, NS2B, and anC
have high antigenic potential while others, particularly prM and
FIGURE 4 | (A) Sequence logo plot of the residues in the block starting at
position 388 of the MSA of NS3 protein sequences.The sequence logo was
generated usingWebLogo (http://weblogo.berkeley.edu/). (B) Shows a
peptide block logo of the peptides in the same block. The block logo was
generated locally using the Block Logo tool. The colors of the amino acids
correspond to their chemical properties: polar amino acids (G, S, T, Y, C, Q,
and N) are shown in green, basic amino acids (K, R, and H) are shown in
blue, acidic amino acids (D and E) are shown in red, and hydrophobic amino
acids (A, V, L, I, P,W, F, and M) are shown in black.
NS2A have low antigenic potential. The 2K protein is predicted to
have only one immuno-functionally conserved block, but it is very
small in size (23 amino acids), resulting in a high conservation to
size ratio.
As the number of peptides in immune-conserved blocks
increases, the higher the entropy. However, blocks that have iden-
tical number of peptides can vary in their entropy due to the
diversity in the set of peptides making up the remaining 1% of the
block excluded from the conserved set. Figure 3 shows blocks in
which some (but not all) peptides are predicted to be epitopes (662
of 3309peptides),blocks inwhich all peptides are predicted to bind
to the same HLA (151 of 3309 peptides), and blocks predicted to
have noHLAbinders (2496 of 3309 peptides). The highest concen-
tration of immune-conserved blocks is found in the body of blocks
conserved by two, three, and four peptides. We can hypothesize
that the immunogenicity of these regions cause higher evolution-
ary pressure, but that in some regions DENV have only limited
space for variability due to possible loss of biological function. This
limited variability means that in many cases the peptide variants
within a given block may have immunogenic potential with the
same HLA restriction and with similar binding afﬁnity, but may
require different T-cell clones for immune recognition. Such pep-
tides make excellent targets for polyvalent vaccines for complete
coverage.
Although the accuracy of the MHC binding prediction algo-
rithm is high, experimental validation of these epitopes should
be performed to ensure ﬁrst that the peptides are processed and
presented to the immune system, and also that they are func-
tional T-cell epitopes. Prediction and experimental validation of
8-, 10-, and 11-mers has yet to be performed. Likewise, prediction
and experimental validation of binding can be extended to MHC
class II.
COMPRESSING ANTIGENIC DIVERSITY FOR VACCINOLOGY
APPLICATIONS
A common approach to designing vaccines against DENV involves
polyvalent constructs (Murrell et al., 2011). The block entropy
method facilitates the design of polyvalent vaccines by iden-
tifying sequences that offer broad coverage of the diversity
of all DENV. An example of a broadly neutralizing DENV
vaccine design is a tetravalent chimeric live attenuated vac-
cine developed by Sanoﬁ Pasteur. The vaccine covers all four
DENV serotypes and offers protection after three doses are
delivered over a 15-months period (Morrison et al., 2010).
The long period between the ﬁrst immunization and protec-
tion state presents a limitation, since the risk of DHF from
natural secondary infection would be signiﬁcantly increased
between the ﬁrst and the last dose. Given these limitations
of current tetravalent vaccine design (four constructs), and
the lack of effective protection with current vaccines, we con-
sidered an additional construct and analyzed blocks which
require up to ﬁve peptides (w = 5) to achieve the accumulative
coverage of 99%. In regions of consecutive conserved blocks,
the peptides can be extended to encompass several conserved
blocks. The extended blocks represent the regions in the DENV
proteins which can be covered by including ﬁve or less pep-
tides in the vaccine construct (Table 6). This analysis can be
performed for u > 5, but such design will include a much
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Table 4 | Conserved blocks with all peptides are predicted (NetMHC) to have high HLA binding affinity.
Protein Block Class I HLA allele
A*02:01 A*03:01 A*11:01 A*24:02 B*07:02 B*08:01 B*15:01
anC 14 3
22 5
45 4
50 3
E 38 4
209 3 3
211 2
237 4 4
258 4
405 3
NS1 33 4
37 4
40 5
161 4*
191 2
224 3
251 4
294 2 2
313 2
NS2B 2 5
14 5 5
29 3
46 4
NS3 43 3
48 2
95 3
130 2
183 4
204 4
217 2
218 2
234 3
238 3
258 1
259 2
263 2
275 4
280 4
281 3
313 3
357 1
358 5
388 5
421 2
422 2
433 4
441 2
(Continued)
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Table 4 | Continued
Protein Block Class I HLA allele
A*02:01 A*03:01 A*11:01 A*24:02 B*07:02 B*08:01 B*15:01
NS3 (cont’d) 447 4
507 5 3
528 5
531 2
536 1 1
593 4
NS4A 39 5
104 2
108 3
2K 5 5
NS4B 2 5
14 5 5
29 3
46 4
NS5 52 3
81 1
86 3 3
116 4 4
117 3
181 4
209 1
300 2 2 2
317 3
318 3 3
325 2
340 3
346 1
393 5
449 1
453 1
460 2
472 1
475 2
477 2 2
489 2
490 3
570 2
587 4
679 3* 5
757 5
759 4
760 4 4 4
765 1
767 1
772 3
849 3
850 3
The number in the cells corresponds to the number of peptides needed to cover 99% of the block in which it is found. For the numbers marked with an asterisks (*),
the least predominant peptide(s) were not predicted to be an MHC binder, but the remaining peptides cover at least 95%.
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Table 5 |The ratio of conservation to size of each DENV protein is
shown.
Protein Fraction of
proteome (%)
Immuno-functionally
conserved blocks (%)
Immuno-functional
conservation:
size ratio
anC 3.36 3.64 1.08
prM 4.89 0.00 0.00
E 14.59 7.27 0.50
NS1 10.38 9.09 0.88
NS2A 6.43 0.00 0.00
NS2B 3.83 4.55 1.19
NS3 18.25 29.09 1.59
NS4A 3.74 2.73 0.73
2K 0.68 0.91 1.34
NS4B 7.34 4.55 0.62
NS5 26.50 38.18 1.44
The conservation to size ratio was calculated by dividing the number of blocks
predicted to be immuno-functionally conserved, divided by the relative size (in
%) of each protein.
larger number of constructs in the polyvalent vaccine. While
the main focus of this work is on the selection of T-cell epi-
tope targets for DENV vaccine development, it also provides a
method which can be used as input for experimental design
of other immunological studies, such as examining immun-
odominance, competitive epitope binding, and detrimental
cross-reactivity.
EXPERIMENTAL SUPPORT OF PRINCIPLE
We examined IEDB and current literature for examples of experi-
mentally validated epitopes and compared them with our results.
We found four examples where predictions correspond to exper-
imental data (Table 7A) and two examples where predictions did
not match fully the experimental data (Table 7B).
The blocks presented in Table 7A consist of four to six pep-
tides with accumulated minimum frequency of 98% that were
both predicted and experimentally validated HLA binders. The
blocks presented in Table 7B consist of three and seven pep-
tides respectively. Common for these two blocks is that one or
more peptides experimentally shown to be HLA binders were
not predicted to be binders. These two blocks, although poten-
tially useful in a polyvalent vaccine construct, where not iden-
tiﬁed as universally binding by the prediction algorithm. The
implication is that the blocks where majority or all of peptides
are identiﬁed as potential binders should be experimentally val-
idated. Conversely, the blocks where majority of peptides are
identiﬁed as non-binders are less likely to be experimental T-cell
epitopes.
CONCLUSION
The analysis of conservation of DENV antigens should consider
both the pan-DENV antigenic diversity and the diversity between
DENVserotypes. Furthermore, functional properties, such asHLA
binding potential are essential for the assessment of immunogenic
potential of antigens. DENV conservation analysis in previous
studies was based on the traditional approach, in which a pep-
tide is classiﬁed as conserved or not conserved based on analysis
of each individual amino acid along with an arbitrary frequency
threshold (typically 90% or higher). The premise of traditional
conservation analysis of vaccine targets is that conserved epitope
candidates are more likely to confer cross-protection between
pathogen variants. We argue that variant inclusion is impor-
tant for polyvalent coverage, since the array of factors making
a peptide immunogenic is far too complex to assume that con-
served predicted binders are automatically the best immunogens.
Our systematic approach, that deploys analysis of conservation of
blocks of peptides, has produced a 10-fold larger number of poten-
tial DENV T-cell epitope targets than the traditional approach.
Similar to a previous benchmark study (Khan et al., 2008), our
method also enables vaccine target discovery that considers both
the conservation of antigens and the immunogenic potential of
these peptides. The peptide blocks determined in our study can
be used to inform and focus the design of experimental stud-
ies of polyvalent dengue vaccines. Furthermore, our approach is
applicable to any variable virus such as HIV, inﬂuenza, or Hepati-
tis C. It is also applicable to broader vaccine approaches such as
identiﬁcation of shared peptide targets across major Flavivirus
pathogens.
The block entropy analysis is an informed strategy for achiev-
ing broad strain coverage in vaccine design with the inclusion
of signiﬁcant but less frequent variants. Central to this approach
is the fact that T-cell epitopes are recognized as peptides rather
than single residues, and should therefore be analyzed as such.
For example, the analysis of 9-mer blocks enables characteriza-
tion of a set of peptides which collectively can be considered
as conserved for immunological applications. In this study, we
based the assessment of immunological potential using predic-
tions of peptide binding to seven common HLA class I molecules
for which prediction algorithms have been validated (Lin et al.,
2008). Some of the conserved blocks contain peptides which
are all predicted to bind the same HLA allele – these blocks
are considered to be immuno-functionally conserved. The pep-
tide block thus becomes a unit of analysis for building com-
binatorial vaccine formulations with broad coverage of both
pathogen variants and diverse HLA haplotypes. This analysis pro-
vides a reasonably sized set of targets that can be experimentally
validated, for example by mass spectrometry (Reinhold et al.,
2010).
The premise for the concept of immuno-functional conser-
vation is not only that all peptides in a block bind to MHC
with the same afﬁnity and HLA restriction, but also that there is
enough redundancy in CTLs so that each epitope/MHC complex
may elicit an equally strong T-cell response. However, immun-
odominance of certain epitopes and some T-cell receptors (TCRs;
Nikolich-Zugich et al., 2004) can lead to an uneven response
to antigens upon vaccination and thus incomplete strain cov-
erage upon challenge. High intra-block homology could allow
for a population of CTLs to recognize all epitope in a block,
which may also favor the concept of including entire immuno-
functionally conserved blocks in a polyvalent vaccine construct.
Hence, predicting the cross-protective capacity of a peptide-
based vaccine gets more difﬁcult as the number of T-cell epitope
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Table 6 | Extended block sequences for string 1.
Extended block ID Protein Position Sequence
1,1 anC 9–69 PPFNMLKRERNRVSTGSQLAKRFSKGLFSGQGPMKLVMAFIAFLRFLAIPPTAGILKRWG
1,2 anC 81–91 GFRKEIGRML
1,3 anC 113–127 FHLTTRNGEPHMIV
1,4 prM 15–27 QERGKSLLFKTA
1,5 prM 30–47 NMCTLIAMDLGELCEDT
1,6 prM 58–79 EPEDIDCWCNLTSTWVTYGTC
1,7 prM 82–120 GEHRRDKRSVALVPHVGMGLETRTETWMSSEGAWKHAQ
1,8 prM 121–132 VETWALRHPGF
1,9 prM 165–213 MRCVGVGNRDFVEGLSGATWVDVVLEHGSCVTTMAKNKPTLDFELIKT
1,10 E 67–79 TTDSRCPTQGEA
1,11 E 94–118 FVDRGWGNGCGLFGKGSLVTCAKF
1,12 E 181–198 LECSPRTGLDFNEMVLL
1,13 E 202–219 KSWLVHKQWFLDLPLPW
1,14 E 233–271 DLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQT
1,15 E 276–292 IFAGHLKCRLKMDKLT
1,16 E 309–320 EVAETQHGTVL
1,17 E 363–377 VNIEAEPPFGDSYI
1,18 E 392–427 KGSSIGKMFEATARGARRMAILGDTAWDFGSVGGV
1,19 E 438–452 FGTAYGVLFSGVSW
1,20 E 460–471 LLTWLGLNSRS
1,21 NS1 8–48 GKELKCGSGIFVTDEVHTWTEQYKFQADSPSKLASAIQKA
1,22 NS1 51–70 GVCGIRSVTRLENIMWKQI
1,23 NS1 111–121 YSWKTWGKAK
1,24 NS1 151–170 WEVEDYGFGVFTTNIWLKL
1,25 NS1 177–210 CDHRLMSAAIKDSKAVHADMGYWIESSKNQTWQ
1,26 NS1 211–222 EKASLIEVKTC
1,27 NS1 223–244 WPKSHTLWSNGVLESEMIIPK
1,28 NS1 250–259 SQHNYRPGY
1,29 NS1 260–276 TQTAGPWHLGKLELDF
1,30 NS1 289–337 CGNRGPSLRTTTASGKLIHEWCCRSCTMPPLRFRGEDGCWYGMEIRPL
1,31 NS2A 90–104 FLRKLTSRETALMV
1,32 NS2A 217–272 SWPLNEGIMAVGMVSILASALLKNDIPMTGPLVAGGLLTVCYVLSGSSADLSLEK
1,33 NS2B 62–72 QAEISGSSPI
1,34 NS2B 76–91 QQEDGSMSIKNEEEE
1,35 NS2B 92–107 MLTILIRTGLLVISG
1,36 NS2B 129–141 AGVLWDVPSPPP
1,37 NS3 29–40 FGYSQIGAGVY
1,38 NS3 41–59 EGVFHTMWHVTRGSVICH
1,39 NS3 60–84 GGRLEPSWASVKKDLISYGGGWRL
1,40 NS3 87–110 WKEGEEVQVIAVEPGKNPRAVQT
1,41 NS3 118–140 TGTIGAIALDFKPGTSGSPIIN
1,42 NS3 141–168 KGKVVGLYGNGVVTKSGDYVSAITQAE
1,43 NS3 182–321 FRKRRLTIMDLHPGAGKTKRYLPAIVREALKRRLRTLILAPTRVVAAEMEEALRGLPIRYQTPAVKSEHTGR
EIVDLMCHATFTMRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVGMGEAAAIFMTATPPGS
1,44 NS3 322–348 DPFPQSNSPIQDEERDIPERSWNTGF
1,45 NS3 353–397 FKGKTVWFVPSIKAGNDIANCLRKNGKKVIQLSRKTFDTEYQKT
1,46 NS3 398–465 LNDWDFVVTTDISEMGANFRADRVIDPRRCLKPVILTDGPERVILAGPMPVTVASAAQRRGRIGRNP
1,47 NS3 466–557 NENDQYIYMGQPLNNDEDHAHWTEAKMLLDNINTPEGIIPALFEPEREKSAAIDGEYRLRGEARKTF
VELMRRGDLPVWLSYKVASAGISY
1,48 NS3 567–618 RNNQILEENMDVEIWTKEGERKKLRPRWLDARVYSDPLALKEFKEFAAGRK
1,49 NS4A 3–13 NLITEMGRLP
1,50 NS4A 20–34 KNALDNIVMLHTTE
(Continued)
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Table 6 | Continued
Extended block ID Protein Position Sequence
1,51 NS4A 38–66 AYQHALSELPETLETLLLLALLGAMTAG
1,52 NS4A 98–141 IQPHWIAASIILEFFLMVLLIPEPEKQRTPQDNQLTYVVIAIL
1,53 2K 22–36 NEMGFLETTKKDLG
1,54 NS4B 27–111 LDVDLRPASAWTLYAVATTVLTPMLRHSIENSSVNVSLTAIANQAAVLMGLDKGWPLSKMDLGVPLLAL
GCYSQVNPLTLTAAV
1,55 NS4B 115–242 AHYAIIGPGLQAKATREAQKRTAAGIMKNPTVDGITVIDLEPIPYDPKFEKQLGQVMLLVLCVTQVLLMR
TTWALCEALTLATGPITTLWEGNPGRFWNTTIAVSMANIFRGSYLAGAGLAFSLIKN
1,56 NS5 3–17 QGETLGEKWKRQLN
1,57 NS5 26–48 YKKSGIQEVDRTEAKEGLKRGE
1,58 NS5 50–70 HHAVSRGSAKLRWFVERNLV
1,59 NS5 71–133 PKGKVVDLGCGRGGWSYYCAGLKKVTEVKGYTKGGPGHEEPIPMATYGWNLVKLHSGVDVFY
1,60 NS5 134–171 PPEKCDTLLCDIGESSSNPTIEEGRTLRVLKMVEPWL
1,61 NS5 174–190 QFCIKVLNPYMPTVIE
1,62 NS5 199–243 GGMLVRNPLSRNSTHEMYWVSNASGNIVSSVNMISRMLINRFTM
1,63 NS5 247–266 ATYEKDVDLGAGTRSVSTE
1,64 NS5 269–282 PDMDIIGKRIEKI
1,65 NS5 288–363 SWHYDQENPYKTWAYHGSYETKQTGSASSMVNGVVKLLTKPWDVIPMVTQMAMTDTTPFGQQR
VFKEKVDTRTPR
1,66 NS5 388–397 PRLCTREEF
1,67 NS5 399–424 KVRSNAAIGAVFTDENKWKSAREAV
1,68 NS5 435–518 ERALHQEGKCETCVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSREN
SLSGVEGEGLHKLGYILR
1,69 NS5 524–548 GGAMYADDTAGWDTRITEDDLQNE
1,70 NS5 564–583 AIFKLTYQNKVVKVLRPTP
1,71 NS5 584–626 GTVMDIISRKDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGV
1,72 NS5 650–672 ERLKRMAISGDDCVVKPIDDRF
1,73 NS5 674–720 ALTALNDMGKVRKDIPQWEPSKGWKDWQQVPFCSHHFHELIMKDGR
1,74 NS5 721–783 LVVPCRNQDELIGRARISQGAGWSLRETACLGKAYAQMWSLMYFHRRDLRLAANAICSAVPV
1,75 NS5 784–816 WVPTSRTTWSIHAHHQWMTTEDMLTVWNRVWI
1,76 NS5 817–826 ENPWMEDKT
1,77 NS5 832–861 DVPYLGKREDQWCGSLIGLTSRATWAKNI
1,78 NS5 878–888 DYMPSMKRFR
The extended block ID is composed of the peptide number (ranging from the most frequent in the given block to the least frequent), followed the block number in
order of starting position from the N-terminal end of the proteome to the C-terminal end. For the extended blocks in the remaining four strings and detailed mapping
of predicted T-cell epitopes, see Table S1 in Supplementary Material. The deﬁnition of the strings and the corresponding extended blocks is described in Section
“Compressing Antigenic Diversity for Vaccinology Applications.”
candidates increases. Furthermore, the larger the combinatorial
space needed to cover the diversity of the four serotypes; the
more complex the task to combine all of the epitopes in one
vaccine without compromising its efﬁcacy. Considering these fac-
tors, we choose to include all blocks in which ﬁve peptides or
less cover 99% of the block. This number maybe subject to
adjustment after proper experimental validation of the epitope
pools.
Applying block entropy analysis to the proteomes of DENV1–4,
yielded 1,732, 1,551, 1,394, and 1,245 conserved blocks of 8-, 9-,
10-, and 11-mer peptides respectively, as opposed to the results of
the benchmark study (Khan et al., 2008) which yielded 206, 165,
118, and 88 conserved 8-, 9-, 10-, and 11-mer peptides respectively,
using the traditional criteria for conservation. Of the 1,551 blocks
of 9-mer peptides, 110 blocks, consisting of 333 peptides, were
predicted to be immuno-functionally conserved, based on their
predicted binding afﬁnity to HLA class I, which can form the
basis of a T-cell-based polyvalent vaccine against DENV. The
method presented here can be readily applied to other relevant
viral pathogens such as inﬂuenza,HIV, or HPV, as well as extended
to encompass MHC class II epitope candidates and functional
B-cell epitopes.
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Table 7 | (A) Examples of experimental evidence supporting the application of the block entropy approach to achieve broad coverage by including
homologous peptide blocks in polyvalent vaccine constructs. In the four examples below, a high percentage of pan-DENV population coverage was
achieved by including only blocks of peptides that have all been predicted, as well as experimentally validated, to bind HLA. Predictions for B*55:02 were
done using netMHCpan 2.4 (PMID: 17726526). (B)Two examples of blocks of experimentally validated epitopes, for which the block entropy approach
failed to account due to epitope predictions inconsistent with the experimental ﬁndings of the respective authors.
Peptides Reference Experimental
HLA
Predicted
affinity (nM)
Predicted
HLA
Block position Pan-DENV peptide
frequency
Protein
A
MLLALIAVL 16493038 A*02:01 10 A*02:01 2151 24.86 NS4A
LLLTLLATV 16493038 A*02:01 9 A*02:01 2151 24.79 NS4A
LLLGLMILL 16493038 A*02:01 14 A*02:01 2151 23.29 NS4A
MLVALLGAM 16493038 A*02:01 300 A*02:01 2151 25.23 NS4A
Accumulated frequency: 98.17
TPEGIIPSM 7529799 B*35:01 49 B*35:01 1977 25.78 NS3
TPEGIIPTL 7529799 B*35:01 345 B*35:01 1977 25.73 NS3
TPEGIIPAL 7544398 B*35 108 B*35:01 1977 48.19 NS3
TPEGIIPSL 7544398 B*35 836 B*35:01 1977 0.15 NS
Accumulated frequency: 99.85
KYTDRKWCF 16517753 A*24 21 A*24:02 2033 23.18 NS3
NYADRKWCF 16517753 A*24 32 A*24:02 2033 7.67 NS3
QYSDRRWCF 16517753 A*24 17 A*24:02 2033 24.89 NS3
SYKDREWCF 16517753 A*24 18 A*24:02 2033 24.99 NS3
NYADRRWCF 11709777 A*24 23 A*24:02 2033 17.62 NS3
Accumulated frequency: 98.35
KPWDIIPMV 17626101 B*55:02 149 B*55:02 2828 0.04 NS5
KPWDVIPMV 17626101 B*55:02 192 B*55:02 2828 51.09 NS5
KPWDVLPMV 17626101 B*55:02 158 B*55:02 2828 0.30 NS5
KPWDVLPTV 17626101 B*55:02 107 B*55:02 2828 7.53 NS5
KPWDVVPMV 17626101 B*55:02 139 B*55:02 2828 38.73 NS5
KPWDVVPTV 17626101 B*55:02 112 B*55:02 2828 1.65 NS5
Accumulated frequency: 99.34
B
FLDLPLPWT 16493038 A*02 64 A*02:01 493 50.13 E
FLDLPLPWL 16493038 A*02 11 A*02:01 493 22.7 E
FFDLPLPWT 16493038 A*02:01 13995 A*02:01 493 23.83 E
Accumulated frequency: 96.66
GTSGSPIIDKK 12808447 A*11 17 A*11:01 1611 9.36 NS3
GTSGSPIVDRK 12808447 A*11 20 A*11:01 1611 14.2 NS3
GTSGSPIVDKK 12808447 A*11 18 A*11:01 1611 2.26 NS3
GTSGSPIADKK 12808447 A*11 22 A*11:01 1611 0.04 NS3
GTSGSPIVNRE 12808447 A*11 18023 A*11:01 1611 24.97 NS3
GTSGSPIINRE 12808447 A*11 18156 A*11:01 1611 23.26 NS3
GTSGSPIINRK 12808447 A*11 16 A*11:01 1611 21.53 NS3
Accumulated frequency: 95.62
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